Literature DB >> 16221544

Where disease pathogenesis meets protein formulation: renal deposition of immunoglobulin aggregates.

Barthélemy Demeule1, Robert Gurny, Tudor Arvinte.   

Abstract

Aggregation is one of the important issues encountered during the development of immunoglobulin-based drugs. The aim of the current review is to discuss the causes and consequences of immunoglobulin aggregation as well as the relevance of immunoglobulin aggregation to disease pathogenesis. Extracellular deposition of immunoglobulins, either monoclonal light chains or intact polyclonal antibodies, induces renal failure in various nephropathies. The aggregates can present fibrillar or amorphous structures. In this review, factors known to influence protein aggregation, such as the primary structure of the protein, local environment and glycosylation are assessed, as well as the subsequent altered clearance, fibril formation and toxicity. The role of the protein local environment is emphasized. Even if the local environment causes only minor perturbations in the protein structure, these perturbations might be sufficient to trigger aggregate formation. This fact underlines the importance of choosing appropriate formulations for protein drugs. If the formulation provides a slightly destabilizing environment to the protein, the long-term stability of the drug may be compromised by aggregate formation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16221544     DOI: 10.1016/j.ejpb.2005.08.008

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  12 in total

1.  Modulation of self-association and subsequent fibril formation in an alanine-rich helical polypeptide.

Authors:  Ayben Top; Kristi L Kiick; Christopher J Roberts
Journal:  Biomacromolecules       Date:  2008-05-02       Impact factor: 6.988

2.  Chemical modifications in therapeutic protein aggregates generated under different stress conditions.

Authors:  Quanzhou Luo; Marisa K Joubert; Riki Stevenson; Randal R Ketchem; Linda O Narhi; Jette Wypych
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

3.  Classification and characterization of therapeutic antibody aggregates.

Authors:  Marisa K Joubert; Quanzhou Luo; Yasser Nashed-Samuel; Jette Wypych; Linda O Narhi
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

4.  Breaking the aggregation of the monoclonal antibody bevacizumab (avastin®) by dexamethasone phosphate: insights from molecular modelling and asymmetrical flow field-flow fractionation.

Authors:  Marieke Veurink; Yvonne Westermaier; Robert Gurny; Leonardo Scapozza
Journal:  Pharm Res       Date:  2013-02-15       Impact factor: 4.200

5.  Rheumatoid arthritis and renal light-chain deposition disease: long-term effectiveness of TNF-α blockade with etanercept.

Authors:  Lorenzo Cavagna; Vincenzo Sepe; Francesca Bobbio-Pallavicini; Filippo Mangione; Roberto Caporali; Carlomaurizio Montecucco
Journal:  Int Urol Nephrol       Date:  2010-06-18       Impact factor: 2.370

6.  Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.

Authors:  Bonnie K Arendt; Marina Ramirez-Alvarado; Laura A Sikkink; Jonathan J Keats; Gregory J Ahmann; Angela Dispenzieri; Rafael Fonseca; Rhett P Ketterling; Ryan A Knudson; Erin M Mulvihill; Renee C Tschumper; Xiaosheng Wu; Steven R Zeldenrust; Diane F Jelinek
Journal:  Blood       Date:  2008-06-20       Impact factor: 22.113

7.  Heavy-chain deposition disease: a morphological, immunofluorescence and ultrastructural assessment.

Authors:  Swapnil Rane; Seema Rana; Chetan Mudrabettu; Vivekananda Jha; Kusum Joshi
Journal:  Clin Kidney J       Date:  2012-10

8.  Sunset Yellow Dye Induces Amorphous Aggregation in β-Lactoglobulin at Acidic pH: A Multi-Techniques Approach.

Authors:  Javed Masood Khan; Ajamaluddin Malik; Fohad Mabood Husain; Mohammed J Hakeem; Abdullah S Alhomida
Journal:  Polymers (Basel)       Date:  2022-01-20       Impact factor: 4.329

9.  Synthesis of Disulfide-Bridging Trehalose Polymers for Antibody and Fab Conjugation Using a Bis-Sulfone ATRP Initiator.

Authors:  Neil L Forsythe; Heather D Maynard
Journal:  Polym Chem       Date:  2021-02-11       Impact factor: 5.582

10.  Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.

Authors:  Marisa K Joubert; Martha Hokom; Catherine Eakin; Lei Zhou; Meghana Deshpande; Matthew P Baker; Theresa J Goletz; Bruce A Kerwin; Naren Chirmule; Linda O Narhi; Vibha Jawa
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.